Cite
HARVARD Citation
Axelsen, L. et al. (2021). Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects. British journal of clinical pharmacology. 87 (1), pp. 119-128. [Online].